Global Lamellar Ichthyosis Market, By Diagnosis (Prenatal Diagnosis, Immunohistochemistry, Skin Biopsy, Others), Treatment (Petrolatum-Based Creams and Ointments, Artificial Tears, Retinoid, Others), Route of Administration (Oral, Topical, Others), End-Users (Clinics, Hospitals, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Lamellar Ichthyosis Market
Lamellar ichthyosis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.60% in the above-mentioned research forecast period. Rising infant rates and increasing number of associated symptoms including depression among others.
Technological advancements and availability of reimbursement for medical devices also boost up the market growth. Moreover increasing research and development, presence of pipeline therapies and rising healthcare expenditure act as opportunity for the market growth. But, side effects associated with treatment options and strict regulatory framework among other may hamper the global lamellar ichthyosis market.
Lamellar ichthyoses is a genetic skin disorder. This has been reported to affect people by birth. Patients suffering from lamellar ichthyosis develop very thick skin over their palms and sole of feet, moreover the skin becomes red, dry and rough. Lamellar ichthyosis can be diagnosed by the prenatal diagnostic method, skin biopsy, ultrasounds among others. Systemic therapy, ocular therapy, topical therapy and surgeries are indicated for treatment of lamellar ichthyosis. Systemic therapies used for lamellar ichthyosis includes oral retinoids involving etretinate, liarozole, isotretinoin among others. Ocular therapies suggested for lamellar ichthyosis treatment includes carboxymethylcellulose sodium, petrolatum, and mineral oil among others. Ointments containing salicylic acid, retinoic acid among others are used as topical therapy for treatment of lamellar ichthyosis. Cicatricial ectropion developed in patients suffering from lamellar ichthyosis can be treated by performing the Apligraf, a human skin equivalent.
The infant population subjected to heredity diseases including lamellar ichthyoses is increasing worldwide. This patient population are largely dependent upon the advanced diagnostic and treatment options and hence expected to provide market with the lucrative growth. It is also estimated that lamellar ichthyosis market is growing with the CAGR of 5.60% in 2020.
This lamellar ichthyosis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Lamellar Ichthyosis Market Scope and Market Size
Lamellar ichthyosis market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of diagnosis, the lamellar ichthyosis market is segmented into prenatal diagnosis, immunohistochemistry, skin biopsy and others.
- On the basis of treatment, the lamellar ichthyosis market is segmented into petrolatum-based creams and ointments, artificial tears, retinoid, others.
- On the basis of route of administration, the lamellar ichthyosis market is segmented into oral, topical and others.
- On the basis of end-users, the lamellar ichthyosis market is segmented into clinics, hospitals, diagnostic centers and others.
- On the basis of distribution channel, the lamellar ichthyosis market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.
Lamellar ichthyosis Market Country Level Analysis
Lamellar ichthyosis market is analysed and market size information is provided by country, treatment, product, site, end-users and distribution channel as referenced above.
The countries covered in the lamellar ichthyosis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the increasing prevalence of lamellar ichthyoses and increasing funding activities by U.S FDA for accelerating the research activities targeting rare diseases. Europe is also expected to the grow due to rising initiative by regulatory agencies and rising number of orphan drug designation to drug manufactured for rare disease treatment.
For instance,
- In August 2018, Krystal Biotech received orphan drug designation for its product candidate KB105 indicated for treatment of ichthyosis in paitent diagnosed with deficiency of transglutaminase 1 (TGM-1). This designation boosted the company’s research and development activities.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Lamellar ichthyosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Lamellar Ichthyosis Market Share Analysis
Lamellar ichthyosis market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to lamellar ichthyosis market.
The major players covered in the lamellar ichthyosis market are Timber Pharmaceuticals LLC, Patagonia Pharmaceuticals, LLC, Galderma, Mayne Pharma Group Limited, Krystal Biotech, LGM Pharma, ANAPTYSBIO, INC., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries, Inc., Teva Pharmaceuticals USA, Inc., Biophore, Sonneborn LLC, Genentech, Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina, Inc, Natera Inc., ELITech Group, ThermoFisher Scientific, Inc., Danaher, PerkinElmer, Inc., Abcam plc, Merck KGaA among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-